Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Relevance

Click to order products descending

Display 45 Products per page

Votrient
Read More
Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis
March 6, 2019
Find out more
Afinitor
Read More
Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to S phase.
March 6, 2019
Find out more
Sutent
Read More
Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3.
March 6, 2019
Find out more
abexinostat
Read More
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone.
March 6, 2019
Find out more
Torisel
Read More
Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.
March 6, 2019
Find out more
Finerenone
Read More
Finerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the detrimental effects due to over-activation of the receptor.
February 27, 2019
Find out more
Farxiga
Read More
Farxiga (dapagliflozin; AstraZeneca) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.
February 27, 2019
Find out more
Jardiance
Read More
Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor originally developed by Boehringer Ingelheim for the treatment of type 2 diabetes.
February 27, 2019
Find out more
Invokana
Read More
Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.
February 27, 2019
Find out more
INCB050465
Read More
INCB050465 (Incyte) is an oral phosphoinositide 3-kinase (PI3K) delta-specific inhibitor. The PI3K pathway has been shown to be highly active in a subset of follicular lymphoma (FL), promoting cell proliferation and survival. INCB050465 inhibits the PI3K-delta isoform with a 20,000-fold selectivity over other PI3K isoforms.
February 10, 2019
Find out more
Venclexta
Read More
Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins.
January 31, 2019
Find out more
Arzerra
Read More
Arzerra (ofatumumab; Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation 20 (CD20) on the B-cell membrane.
January 31, 2019
Find out more
Calquence
Read More
Calquence (acalabrutinib; AstraZeneca/Acerta) is a novel, orally available, second-generation Bruton’s tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Inhibition of the BTK protein prevents the activation of the B-cell antigen receptor signaling pathway, which blocks both B-cell activation and BTK-mediated activation of downstream survival pathways.
January 31, 2019
Find out more
Copiktra
Read More
Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme.
January 31, 2019
Find out more
Zanubrutinib
Read More
Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK), developed to be more selective with less off-target effects than Imbruvica (ibrutinib; AbbVie/Johnson & Johnson). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.
January 31, 2019
Find out more
Betalutin
Read More
Betalutin is a first-in-class antibody-radionucleotide conjugate targeted to CD37, an alternative to CD20, which is widely targeted in non-Hodgkin’s lymphoma. CD37 is highly expressed in B cells and B-cell lymphomas.
January 31, 2019
Find out more
Aliqopa
Read More
Aliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial for normal B-cell development, and is subverted by follicular lymphoma (FL) to promote survival and growth.
January 31, 2019
Find out more
Gazyva
Read More
Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope of the CD20 antigen.
January 31, 2019
Find out more
Rituxan
Read More
Rituxan (rituximab; Roche/Biogen/Chugai/Zenyaku Kogyo) is a chimeric monoclonal antibody that binds to the cluster of differentiation (CD)20 antigen, which regulates cell cycle initiation and may function as a calcium ion channel. CD20 is not found on normal plasma cells or normal tissue, but is expressed on over 90% of B-cell non-Hodgkin’s lymphomas (NHLs).
January 31, 2019
Find out more
Zydelig
Read More
Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased phosphorylation Akt and other downstream effectors, an increase in poly (ADP-ribose) polymerase and caspase cleavage, and an induction of apoptosis.
January 31, 2019
Find out more
Imbruvica
Read More
Imbruvica is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.
January 31, 2019
Find out more
Ublituximab
Read More
Ublituximab (TG Therapeutics) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications.
January 31, 2019
Find out more
Treanda/Bendeka
Read More
Treanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent.
January 31, 2019
Find out more
Kymriah
Read More
Kymriah (tisagenlecleucel; Novartis) is a cluster of differentiation (CD)19-targeted genetically modified autologous T-cell immunotherapy, comprised of a murine single-chain antibody fragment that binds CD19 and is linked to intracellular signaling domains from 4-1BB (CD137) and CD3 zeta.
January 31, 2019
Find out more
Revlimid
Read More
Revlimid (lenalidomide; Celgene) is an oral thalidomide analog with antineoplastic, immunomodulatory, and anti-angiogenic properties.
January 30, 2019
Find out more
Zevalin
Read More
Zevalin (ibritumomab tiuxetan; Acrotech Biopharma/Mundipharma) is an intravenous radioactive agent consisting of the murine monoclonal antibody (MAb) ibritumomab, which is covalently linked to the chelator tiuxetan.
January 30, 2019
Find out more
lisocabtagene maraleucel
Read More
Lisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market following the launches of approved CAR-T drugs Kymriah (tisagenlecleucel; Novartis) and Yescarta (axicabtagene ciloleucel; Gilead).
January 30, 2019
Find out more
umbralisib
Read More
Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform plays a role in B-cell development and function, and is often overactivated in B-cell malignancies.
January 30, 2019
Find out more
Yescarta
Read More
Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.
January 30, 2019
Find out more
MT-2271
Read More
MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma. It contains a mix of recombinant hemagglutinin proteins expressed as VLPs.
January 14, 2019
Find out more
Flublok
Read More
Flublok (Sanofi) is a quadrivalent recombinant seasonal influenza vaccine that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
Fluzone High-Dose
Read More
Fluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
Flucelvax QIV
Read More
Flucelvax is an inactivated subunit cell-based QIV that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
FluMist QIV
Read More
FluMist QIV (AstraZeneca/Daiichi Sankyo) is a quadrivalent live-attenuated influenza vaccine containing antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
Fluad QIV
Read More
Fluad QIV (CSL) is a subunit, surface antigen-containing seasonal quadrivalent influenza vaccine adjuvanted with MF-59, an oil-in-water emulsion. It contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
GSK-3
Read More
GSK-3 is a 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine, which also includes the conserved, unconjugated pneumococcal proteins dPly and PhtD.
December 21, 2018
Find out more
V114
Read More
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
December 21, 2018
Find out more
Prevnar 13
Read More
Prevnar 13 is Pfizer’s follow-on vaccine to Prevnar 7, which was the first pneumococcal conjugate vaccine licensed in the US.
December 21, 2018
Find out more
Synflorix
Read More
Synflorix (GlaxoSmithKline/Japan Vaccine) is a 10-valent pneumococcal conjugate vaccine active against Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
December 21, 2018
Find out more
Pneumovax 23
Read More
Pneumovax 23 is a 23-valent polysaccharide vaccine containing 23 purified capsular antigens of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F.
December 21, 2018
Find out more
PF-06482077
Read More
Pfizer’s PF-06482077 is a 20-valent pneumococcal conjugate vaccine, which is currently in Phase II development in the US and EU. PF-06482077 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as seven additional serotypes.
December 21, 2018
Find out more
Evinacumab
Read More
Evinacumab (Regeneron) is a monoclonal antibody (MAb) that inhibits angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is secreted naturally by the liver and acts as a partial inhibitor of lipoprotein lipase and endothelial lipase.
November 20, 2018
Find out more
Epanova
Read More
Epanova (omefas; AstraZeneca) is an omega-3 fatty acid drug developed for the treatment of severe hypertriglyceridemia. It contains a novel free fatty acid formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
November 20, 2018
Find out more
ralinepag
Read More
Ralinepag (Arena Pharmaceuticals/Everest Medicines) is a selective prostaglandin I2 receptor agonist. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, which also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
October 29, 2018
Find out more
esuberaprost
Read More
Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, and also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.
October 29, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *